Media stories about Neos Therapeutics (NASDAQ:NEOS) have trended positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Neos Therapeutics earned a coverage optimism score of 0.34 on Accern’s scale. Accern also assigned headlines about the company an impact score of 44.638369943909 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Neos Therapeutics (NASDAQ:NEOS) opened at $9.25 on Friday. The stock has a market cap of $265.35 and a price-to-earnings ratio of -2.70. Neos Therapeutics has a 52 week low of $5.20 and a 52 week high of $13.15. The company has a debt-to-equity ratio of 4.01, a quick ratio of 2.14 and a current ratio of 2.42.
NEOS has been the subject of several analyst reports. Cantor Fitzgerald set a $20.00 price target on shares of Neos Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 1st. BidaskClub raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 27th. BMO Capital Markets downgraded shares of Neos Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 31st. Zacks Investment Research downgraded shares of Neos Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 25th. Finally, Cowen reaffirmed a “buy” rating on shares of Neos Therapeutics in a research note on Thursday, October 26th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Neos Therapeutics has an average rating of “Hold” and a consensus price target of $14.00.
TRADEMARK VIOLATION WARNING: “Neos Therapeutics (NEOS) Receiving Positive Media Coverage, Report Shows” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.com-unik.info/2018/02/17/neos-therapeutics-neos-receiving-positive-media-coverage-report-shows.html.
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.